A peptide the body makes inside its own mitochondria flipped exactly the metabolic switch it was supposed to flip in worn-out stem cells. The cells got worse anyway. They divided less, aged faster, and turned more inflammatory, and when they were injected into injured mouse kidneys they failed to repair anything.
That result, published June 22 in Inflammation and Regeneration ↗, is a useful brake on a popular idea: that switching on a cell's energy machinery is the same as making the cell young and functional again.
The peptide is MOTS-c ↗, a short string the body encodes inside the mitochondrial genome rather than the nucleus. It activates AMPK, the enzyme cells use as a fuel gauge, and it has built a following as an exercise-mimicking, longevity-adjacent compound. The cells in question are mesenchymal stromal cells, or MSCs, the fat- and marrow-derived cells that regenerative medicine injects to calm inflammation and rebuild tissue. Their healing power leans heavily on healthy mitochondria, and obesity is known to wreck that machinery. So the hypothesis was clean: take MSCs from people with obesity, restore MOTS-c, and the cells should recover.
The team took MSCs from the abdominal fat of donors with obesity (body mass index 30 or above) and from lean donors, six per group, and confirmed that the obese cells started with lower MOTS-c levels. Adding the peptide back did the expected metabolic thing. It restored intracellular MOTS-c and switched on AMPK signaling. Then it did the opposite of rescue. Treated cells slowed their proliferation, ramped up the senescence genes p16 and p21 (the markers of cells that have stopped dividing and started leaking inflammatory signals), and raised the inflammatory cytokine TNF-alpha.
The animal test was harsher. In mice with renal artery stenosis, a narrowed-kidney-artery model used to study chronic kidney injury, MOTS-c-pretreated MSCs from obese donors did not improve blood flow, scarring, or tubule damage. Worse, the same pretreatment blunted the repair ability of MSCs taken from lean donors, the cells that work fine on their own. The peptide did not just fail to fix the broken cells. It degraded the healthy ones.
The authors call this a "dissociation between metabolic activation and functional stemness." The metabolic gauge moved. The thing that actually matters for a cell therapy, its capacity to repair tissue, moved the other way. Restoring a single mitochondrial signal, they conclude, is not enough to undo obesity-driven cell dysfunction and can make it worse.
This is one preclinical study with six donors per group and a single peptide dose, so it is a signal about mechanism, not a verdict on MOTS-c in people. But it lands on a peptide that does not usually get this kind of scrutiny. MOTS-c is one of a small family of mitochondrial-derived peptides, the best known of which is humanin ↗, and it sits on peptidemodel among the mitochondrial ↗ and longevity peptides, a class sold and self-injected well ahead of the evidence. JAMA recently described that injectable-peptide market as a regulatory gray zone ↗. A finding that the same molecule can activate the right pathway while quietly pushing cells toward senescence is exactly the kind of detail that gets lost when a peptide is marketed on its mechanism rather than its outcomes.
The narrow lesson is about cell therapy: dosing donor MSCs with MOTS-c before transplant looks like a bad idea, at least in this model. The broader one is older and keeps needing to be relearned. A pathway lighting up is not the same as a cell, or a person, getting better.